Premium
Urinary glycylprolyl dipeptidyl aminopeptidase (GP‐DAP) in insulin‐dependent diabetic patients
Author(s) -
Nukada O,
Kobayashi M,
Moriwake T,
Kanzaki S,
Himei H,
Yoda T,
Seino Y
Publication year - 1992
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1992.tb12133.x
Subject(s) - medicine , urinary system , fructosamine , diabetes mellitus , microalbuminuria , endocrinology , urine , dipeptidyl peptidase , gastroenterology , urology , enzyme , biochemistry , biology
Urinary glycylprolyl dipeptidyl aminopeptidase (GP‐DAP) concentrations were determined in 36 insulin‐dependent diabetic children aged 4–18 years with a duration of diabetes ranging from 1 month to 14 years. Abnormal urinary GP‐DAP concentrations were found in 19 of the 36 patients. Twelve of 27 patients without microalbuminuria also had increased urinary concentrations of GP‐DAP. There was a significant correlation between urinary GP‐DAP and plasma fructosamine ( r = 0.52, p < 0.001). Our data suggest that urinary GP‐DAP may be used as a marker for diabetic nephropathy. However, there is also a possibility that increased urinary GP‐DAP concentrations are functionally related to poor metabolic control. Longitudinal studies are needed to establish the clinical usefulness of urinary GP‐DAP.